IRL-Dublin: technical analysis services

Country:

Ireland

City/Locality:

DOYBLINO

Notice/Contract Number:

eu:141680-2008

Publication Date:

Jun 3, 2008

Buyer:

DEPARTMENT OF FOREIGN AFFAIRS

Original Language:

English

Address:

DEPARTMENT OF FOREIGN AFFAIRS
DUBLIN , IRELAND
Ireland

Web Site:

http://www.dfa.ie

Notice Type: 2280
-
Contract award
Regulation of Procurement: European Communities, with participation by GPA countries
EU Official Journal Publication: 106/2008
, #
141680-2008
Referenced Document Number: 170778-2007
Contract Nature: Service contract
Procedure Type: Contract awards
Type of Bid Required: Not applicable
Awarding Criteria: The most economic tender
Successful Bidder: NAME AND ADDRESS OF ECONOMIC OPERATOR TO WHOM THE CONTRACT HAS BEEN
AWARDED: FSG Social Impact Advisors, 20 Park Plaza, Suite 320, US-MA 02116
Boston. Tel. 161 73 57 40 00.

Summary:
CONTRACT AWARD NOTICE
Services
SECTION I: CONTRACTING AUTHORITY
I.1) NAME, ADDRESSES AND CONTACT POINT(S): Department of Foreign Affairs,
Bishop's Square, Redmond's Hill, Attn: Sean Creaney, IRL-Dublin 2. Tel.
(353-1) 408 26 45. E-mail: sean.creaney@dfa.ie. Fax (353-1) 408 28 84.
Internet address(es):
General address of the contracting authority: http://www.dfa.ie.
Address of the buyer profile: http://www.etenders.gov.ie/search/
Search_AuthProfile.aspx?ID=AA01498.
I.2) TYPE OF THE CONTRACTING AUTHORITY AND MAIN ACTIVITY OR ACTIVITIES:
Ministry or any other national or federal authority, including their
regional or local sub-divisions.
General public services.
The contracting authority is purchasing on behalf of other contracting
authorities: yes.
SECTION II: OBJECT OF THE CONTRACT
II.1) DESCRIPTION
II.1.1) Title attributed to the contract by the contracting authority:
Evaluation of International Partnership for Microbicides.
II.1.2) Type of contract and location of works, place of delivery or of
performance: Services.
Service category No 27.
Main place of performance: Ireland.
NUTS code IE.
II.1.4) Short description of the contract or purchase(s): The primary
purpose of this evaluation is for both IPM and its funders to take
independent stock of achievements since its establishment 5 years ago. It
will draw relevant lessons to inform choices as it looks ahead, such as
how to define its optimal strategic role in microbicide development (and
how this could be realised), including how the organisation functions.
After a quarter century of the HIV pandemic, prevention efforts have
failed to curb its relentless spread. Whilst there have been successes,
these have been isolated and gains in many settings are now under threat
for a variety of reasons. To complement behaviour change, only a limited
number of effective biomedical prevention technologies have been developed
and made available, but these have fallen short of delivering global
control. The worldwide trend has been an increasing feminisation of this
pandemic with women in developing countries most hard hit. The exaggerated
vulnerability of young women in particular is reflected in the sobering
statistics.
The case for new prevention tools for HIV and microbicides against HIV in
particular has been universally accepted and underlined by UNAIDS in its
prevention strategy and in a number of international fora including; the
United Nations General Assembly Special Session on HIV and AIDS (UNGASS),
the G8 Summit and recent annual International AIDS Meetings and
Conferences. There is a technical and political imperative to pursue the
search for a microbicide effective against HIV and for it to be made
available to the world's most disadvantaged and vulnerable women. At this
stage vaginal microbicides and/or pre-exposure prophylaxis are prioritised
ahead of rectal products although there is recognition that anal sex is a
significant feature of heterosexual and same-sex relationships.
Whilst the science to develop HIV preventive microbicides has been active
for the best part of 2 decades, championed by a relatively small group of
passionate product development researchers, the last 5 years have
witnessed a spectacular jump in interest, activity and corresponding
resources. Although the microbicides field has benefited generally from
remarkable successes in mobilising additional finance for health and
HIV/AIDS, new microbicides-specific advocacy efforts, organisations,
partnerships and strategies have delivered unprecedented and growing
support for the development of microbicides. Furthermore the past decade
has witnessed an impressive variety and number of Global Health
Partnerships established to address priority diseases of poverty. A
selection of these are product development public-private-partnerships
(referred to as PDPs). Current available evidence indicates that PDPs
bring efficiencies and acceleration to hitherto neglected product
development areas.
The International Partnership for Microbicides (IPM), established in 2002
and based in Silver Spring, Maryland, USA, has become a prominent player
in the microbicide field having been instrumental in a number of
field-wide developments and certain product focussed progress. A
non-profit PDP, IPM's goal has remained unchanged; to accelerate the
development of and access to effective microbicides for women living in
the world's poorest settings. IPM has variously and at different times
been referred to as a scientific convenor, knowledge hub, a catalyst,
broker, venture capital company, advocate and in some quarters, a
reasonable one-stop-shop for microbicides. However it is best recognised
as a virtual international pharmaceutical company that applies a global
approach to its business and the microbicides field in its primary mission
to bring the day forward when women in high incidence settings will
effectively protect themselves from HIV with a vaginal microbicide.
IPM has secured support from public bodies, multilateral UN agencies,
private philanthropy and for-profit private companies. Regarding direct
funding, IPM has secured 217 000 000 USD (165 000 000 EUR) in confirmed
commitments to date and has received approximately 147 000 000 USD(110 000
000 EUR). IPM's funding aries from un-earmarked to tightly earmarked
support. Product "donation" agreements have been made with Tibotec
Pharmaceuticals Ltd, Merck & Co., Inc, Gilead Sciences, Inc. and
Bristol-Meyers Squibb.
NOTE: Further information relating to this notice may be available on the
eTenders Web Site at http://www.etenders.gov.ie/Search/
Search_Switch.aspx?ID=67149.
II.1.5) Common procurement vocabulary (CPV): 74312100, 85100000,
85148000, 85149000, 85323000, 73200000, 73000000.
II.1.6) Contract covered by the Government Procurement Agreement (GPA):
Yes.
II.2) TOTAL FINAL VALUE OF CONTRACT(S)
II.2.1) Total final value of contract(s): Value: 230 000 EUR.
Excluding VAT.
SECTION IV: PROCEDURE
IV.1) TYPE OF PROCEDURE
IV.1.1) Type of procedure: Open.
IV.2) AWARD CRITERIA
IV.2.1) Award criteria: The most economically advantageous tender in
terms of
1. Quality of Proposal. Weighting: 35 %.
2. Quality and Balance of team. Weighting: 35 %.
3. Ability to meet timescale. Weighting: 10 %.
4. Cost/vfm. Weighting: 20 %.
IV.3) ADMINISTRATIVE INFORMATION
IV.3.1) File reference number attributed by the Contracting Authority:
IV.3.2) Previous publication(s) concerning the same contract: Contract
notice
Notice number in OJ: 2007/S 138-170778 of 20.7.2007.
SECTION V: AWARD OF CONTRACT
CONTRACT NO: 0301
TITLE: Evaluation of International Partnership for Microbicides.
V.1) DATE OF CONTRACT AWARD: 2.4.2008.
V.2) NUMBER OF OFFERS RECEIVED: 2.
V.3) NAME AND ADDRESS OF ECONOMIC OPERATOR TO WHOM THE CONTRACT HAS BEEN
AWARDED: FSG Social Impact Advisors, 20 Park Plaza, Suite 320, US-MA 02116
Boston. Tel. 161 73 57 40 00.
V.4) INFORMATION ON VALUE OF CONTRACT Initial estimated total value of
the contract:
Value: 200 000 EUR.
Excluding VAT.
Total final value of the contract:
Value: 230 000 EUR.
Excluding VAT.
If annual or monthly value:
SECTION VI: COMPLEMENTARY INFORMATION
VI.2) ADDITIONAL INFORMATION: The purchasing authority is acting on
behalf of the following organisations:
Iriash Aid, CIDA, NORAD, Netherlands, DFID, Denmark and Gates Foundation.
(ET Ref: 67149.).
VI.3) PROCEDURES FOR APPEAL:
VI.3.1) Body responsible for appeal procedures: The High Court, Four
Courts, IRL-Dublin 7. E-mail: SupremeandHighCourtOperations@courts.ie.
Tel. (353-1) 888 60 89. URL: www.courts.ie. Fax (353-1) 888 60 88.
VI.3.3) Service from which information about the lodging of appeals may
be obtained: The Courts Service, 15/24 Phoenix Street North, Smithfield,
IRL-Dublin 7. E-mail: SupremeandHighCourtOperations@courts.ie. Tel.
(353-1) 888 60 89. URL: www.courts.ie. Fax (353-1) 888 60 88.
VI.4) DATE OF DISPATCH OF THIS NOTICE: 2.6.2008.

IRL-Dublin: technical analysis services

Contract Award

General Information

Contact Information

Goods, Works and Services

Original Text

dgMarket - Tenders and consulting opportunities worldwide